Oruka Therapeutics Insider Arjun Agarwal Sells Shares
Arjun Agarwal sold 395 shares of Oruka Therapeutics as part of a planned sale.
Key Points
- Arjun Agarwal, Senior VP of Finance at Oruka Therapeutics, sold 395 shares valued at $27,527.55 on June 15, 2026.
- Oruka Therapeutics trades on NasdaqGM with a market cap of $4.22 billion and a 52-week range of $10.77 to $91.00.
- Analysts maintain strong buy ratings, with BTIG setting a price target of $151 as of May 14, 2026.
On June 15, 2026, Arjun Agarwal, the Senior Vice President of Finance at Oruka Therapeutics, Inc. (NasdaqGM: ORKA), sold 395 shares of the company's stock. This planned transaction was executed at an average price of $69.69 per share, totaling $27,527.55.
Insider Buying and Selling at Oruka Therapeutics, Inc.
Arjun Agarwal wasn't the only insider trading shares of Oruka Therapeutics. On the same day, Joana Goncalves, the Chief Medical Officer, bought 7,000 shares at $7.32 each. She also sold 3,500 shares, though the transaction price wasn't disclosed. Additionally, Laura Lee Sandler, the Chief Operating Officer, sold 600 shares at $69.69, and Paul Quinlan, General Counsel, sold 733 shares at the same price. These transactions were not part of pre-arranged plans.
Oruka Therapeutics Stock Snapshot
Shares of Oruka Therapeutics, Inc. traded near $69.89, with the company boasting a market cap of $4.22 billion. Currently, the stock has a forward P/E ratio that is not meaningful due to negative earnings. The stock's 52-week range is $10.77 to $91.00, and it has 50-day and 200-day moving averages of $63.70 and $37.60, respectively. With a current ratio of 23.76 and a debt-to-equity ratio of 0.37, Oruka appears financially stable.
Analysts Set New Price Targets
On May 14, 2026, BTIG reiterated its buy rating on Oruka Therapeutics with a price target of $151. Other analysts, including HC Wainwright & Co. and UBS, have maintained buy ratings with targets of $120 and $100, respectively. The consensus among 12 analysts is a strong buy, with a mean target price of $142.17.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California. It focuses on developing novel monoclonal antibody therapies for psoriasis and other inflammatory conditions. The company's leading products include ORKA-001 and ORKA-002, both in phase 2 trials for various conditions. Oruka is led by CEO Dr. Lawrence Otto Klein and employs 68 people.
Bottom Line
Arjun Agarwal's recent share sale at Oruka Therapeutics was part of a planned transaction, reflecting typical insider activity. Oruka remains a company of interest due to its significant market presence and ongoing clinical trials. Investors often track insider sales to gauge executive sentiment, but these transactions are not definitive indicators of future stock performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.